Genetic Test Panels at AdvaGenix

AdvaGenix is the first to offer next-generation sequencing, Sanger sequencing and qPCR for all genetic testing. This advanced technology is available for:

  • Diagnostic gene testing.
  • Reproductive health testing.
  • Personalized medicine.
  • Cancer testing.
  • Whole genome and clinical exome sequencing.
  • Pharmacogenomics.

Below are full explanations of each test and the number of genes they include.

Jump ahead:

Cancer | Diagnostic gene testing | Reproductive health | Pharmacogenomics & metabolism | Neurological disorders


Hereditary cancer gene panels

  • Comprehensive 138 inherited genes panel for eight major organ systems.
  • Oncogene sequencing multi-gene with BRCA1/2 (32 genes).
  • (30 genes).
  • Lynch cancer panel (54 genes).
  • Colon cancer panels (11 genes).
  • Colon plus cancer panel (29 genes).
  • Breast/ovarian uterine full panel (22 genes).
  • Breast plus cancer panel (12 genes).
  • Ovarian cancer panel (21 genes).
  • BRCA cancer panel (2 genes).
  • Prostate cancer panel (19 genes).
  • Comprehensive hereditary cancer gene panel (176 genes).
  • Whole exome hereditary cancer gene panel across all organ systems (877 genes).

Organ system specific hereditary gene panels (breast and other female organs)

  • Basic breast cancer panel (2 genes).
  • Expended high risk breast cancer panel (9 genes).
  • Genes associated with hereditary breast, ovarian, endometrial and fallopian tube cancers (35 genes).

Endocrine organ panel

  • Panel of genes associated with hereditary paraganglioma-pheochromocytoma syndrome, hereditary hyperparathyroidism, thyroid and parathyroid cancers, and other endocrine cancers (28 genes).

Gastrointestinal organ panels

  • Panel of genes associated with actionable risk of developing colorectal and other associated cancers, such as ovarian, endometrial and thyroid (26 genes).
  • Panel of genes associated with hereditary gastric cancer and other cancer types (19 genes).
  • Panel of genes associated with hereditary pancreatic cancer, exocrine tumors and pancreatic neuroendocrine cancers, and chronic pancreatitis (28 genes).

Hematological tumor panel

  • Panel of genes associated with a predisposition to myelodysplastic syndrome, leukemia and lymphoma.

Skin

  • Panel of genes associated with a lifetime risk of developing melanomas as well as other cancers (12 genes).

Nervous system

  • Panel of genes associated with hereditary paraganglioma-pheochromocytoma syndrome (14 genes).
  • Panel of genes associated with hereditary brain tumor panel (27 genes).
  • Panel of genes associated with hereditary cancers of the central and peripheral nervous system brain (40 genes).

Pediatric cancers

  • Comprehensive hereditary pediatric cancer panel including solid tumors, soft tissue tumors and hematologic cancers (56 genes).
  • Panel of 32 genes associated with hereditary pediatric cancers of the central and peripheral nervous system (32 genes).
  • Panel of 16 genes associated with a predisposition to childhood hematologic cancers (16 genes).
  • Panel of 48 genes associated with predisposition to pediatric solid tumors.

Genitourinary (GU) system

  • Panel of genes associated with inherited prostate cancer and an increased lifetime risk of developing prostate cancer or other cancers (15 genes).
  • Panel of genes associated with hereditary renal or urinary tract cancers, including cancers of the kidneys, renal pelvis, ureters, bladder and ureter (30 genes).

Soft tissue malignancy (sarcomas)

  • Panel of genes associated with hereditary sarcomas, including bone and soft tissue sarcomas (41 genes).

Cancer somatic gene abnormalities

Solid tissue tumors

  • Comprehensive panel for solid tumors (67 genes).

Organ specific solid tissue tumor gene panel

  • Lung tumor panel (26 genes).
  • Brain tumor panel (37 genes).
  • Breast tumor panel (24 genes).
  • Cervical tumor panel (23 genes).
  • Ovarian tumor panel (24 genes).
  • Endometrial tumor panel (22 genes).
  • Esophagus tumor panel (25 genes).
  • Gastric tumor panel (25 genes).
  • Colorectal tumor panel (25 genes).
  • Liver/biliary tumor panel (25 genes).
  • Pancreatic tumor panel (27 genes).
  • Head and neck tumor panel (26 genes).
  • Melanoma panel (19 genes).
  • Thyroid tumor panel (17 genes).

Hematologic tumors

  • Comprehensive gene panel for hematologic tumors (76 genes).
  • Panels for specific hematologic tumors.
    • Acute myeloid leukemia (AML, 29 genes).
    • Chronic lymphocytic leukemia (CLL, 11 genes).
    • Juvenile myelomonocyte leukemia (JMML, 15 genes).
    • Lymphoma (8 genes).
    • Myelodysplastic syndrome/chronic myelomonocyte leukemia (MDS/CMML, 31 genes).
    • Myeloproliferative neoplasms (MPN, 24 genes).

Fusion gene panels

  • Comprehensive fusion gene panel (152 genes).
  • Individual fusion gene panels.
    • Comprehensive sarcoma fusion panel (27 genes).
    • Comprehensive solid tumor fusion gene panel (54 genes).
    • Comprehensive hematologic neoplasm fusion gene panel (76 genes).
      • Individual hematologic tumor fusion gene panels.
        • Acute lymphoblastic leukemia (ALL, 45 genes).
        • Myeloproliferative neoplasms (PMN, 39 genes).
        • Lymphomas (32 genes).

Cell free tumor DNA (cfDNA) assays

  • Pan-cancer cfDNA assay for solid tumors (52 genes).
  • Organ specific cfDNA cancer gene panels
    • Lung cancer cfDNA assay panel (11 genes).
    • Breast cancer cfDNA assay panel (10 genes).
    • Colon cancer cfDNA assay panel (14 genes).
  • cfDNA assays for hematologic diseases.
  • Pan-hematological disease cfDNA assay (60 genes).
  • Hematological disease specific cfDNA assays
    • AML profile (24 genes); MDS/CMML profile (31 genes).
    • Myeloid disorders profile (56 genes).

Tests for cancer immunotherapy

  • Tumor mutation burdan (tmb).
  • Immunohistochemical stains: pd-l1, pd-1.

Fluorescence in situ hybridization (FISH)


Diagnostic gene testing

A genetic disease or disorder is the result of mutations or alterations in an individual’s DNA. There are more than 10,000 different genetic conditions.

Genetics 101

Cardiovascular diseases

Arrhythmia panels

  • Basic arrhythmia panel (47 genes).
  • Comprehensive arrhythmia panel (176 genes).

Cardiomyopathy panels

  • Basic cardiomyopathy panel (94 genes).
  • Comprehensive cardiomyopathy panel (227 genes).

Combined cardiomyopathy and arrhythmia panel

  • Basic combined cardiomyopathy and arrhythmia panel (131 genes).
  • Comprehensive cardiomyopathy and arrhythmia panel (224 genes).

Combined cardiovascular panels

  • Basic combined cardiovascular panel (106 genes).
  • Comprehensive combined cardiovascular panel (241 genes).

Panels for individual cardiovascular diseases

  • Arrhythmogenic right ventricular cardiomyopathy (ARVC, 14 genes).
  • Catecholaminergic polymorphic ventricular tachycardia (CPVT, 8 genes).
  • Dilated cardiomyopathy (DCM, 66 genes).
  • Familial hypercholesterolemia (FH, 4 genes).
  • Hypertrophic cardiomyopathy (HCM).
  • Left ventricular non-compaction (LVNC) (8 genes).
  • Thoracic aortic aneurysms and dissections (TAAD)/Marfan syndrome and related disorders (24 genes).
  • Brugada syndrome (BrS, 14 genes).
  • Long QT syndrome (LQTS, 17 genes).
  • Short QT syndrome (SQTS, 5 genes).
  • Noonan Spectrum and RASopathies panel (19 genes).
  • Heritable disorders of connective tissue (HDCT, 49 genes).
  • Sudden cardiac arrest panel (13 genes).

Neurological disorders

  • Epilepsy panels
    • Febrile seizure (13 genes).
    • Infantile epilepsy (113 genes).
    • Childhood-onset epilepsy panel (82 genes).
    • STAT epilepsy panel (26 genes).
    • Comprehensive epilepsy panel (149 genes).
  • Hearing loss (126 genes).
  • Autism panel (116 genes).
  • Intellectual disability panel (140 genes).

Reproductive health

Prenatal tests

  • Non-invasive prenatal test (NIPT).
  • Prenatal significant genetic disorder panel (30 genes/49 disorders).

Carrier screening

  • AOCG/AOMG recommended panel (27 genes).
  • Expanded carrier screening panel (250 genes).
  • Whole exome carrier screening panel (2,100 genes).

Pharmacogenetics & metabolic issues

  • Comprehensive pharmacogenetics panel (45 genes).
  • Comprehensive panel of inborn errors of metabolism (594 genes).

Whole genome & clinical exome sequencing

Potential utilization:

  • PHARMA research.
  • Genetic diseases.
  • Non-medical health check-up.
  • Metagenomics for use of genomic identification of infectious microorganisms.